NLE Endocrine & Metabolic Nursing — Pituitary, Thyroid & Parathyroid DisordersSummary

ADH is released from the posterior pituitary in response to increased serum osmolality or decreased blood volume. Its primary action is to increase the permeability of the kidney's collecting duct, promoting water reabsorption. This results in decreased urine output and increased serum osmolality normalization. The hormone acts on V2 receptors in the kidney. Understanding ADH's mechanism is foundational because both SIADH and diabetes insipidus are disorders of dysregulation or response to this single hormone, making them true mirror images of each other.

SIADH occurs when there is excessive, inappropriate release of ADH despite normal or low serum osmolality. The kidney retains water, diluting the blood and lowering serum sodium (dilutional hyponatremia). Urine is inappropriately concentrated (high specific gravity and osmolality) while serum osmolality is low. Common causes include small-cell lung cancer, CNS disorders (meningitis, encephalitis, head trauma), surgery, pain, stress, and certain medications (SSRIs, carbamazepine). The pathophysiology is straightforward: more ADH → more water reabsorption → dilution of plasma → low sodium.

DI results from deficient ADH (central/neurogenic DI) or renal unresponsiveness to ADH (nephrogenic DI). Without adequate ADH effect, the kidneys cannot concentrate urine. The result is massive polyuria (3–20 L/day) of very dilute urine (low specific gravity <1.005), combined with intense thirst (polydipsia). If the patient cannot drink enough water (e.g., altered consciousness, restricted access), hypernatremia and dehydration develop. The serum osmolality is high; urine osmolality is low. Note: DI is unrelated to diabetes mellitus despite the similar name—it is a water-balance disorder, not a glucose disorder.

The thyroid produces T4 (thyroxine, 80% of output) and T3 (triiodothyronine, more potent, 20% of output). These hormones increase metabolic rate, heat production, oxygen consumption, and sympathetic activity. The anterior pituitary secretes TSH in response to TRH from the hypothalamus. Elevated thyroid hormone suppresses TSH (negative feedback). In primary thyroid disease, the feedback loop is intact, so TSH and thyroid hormone move in opposite directions: high TSH usually indicates an underactive thyroid (hypothyroidism); low TSH indicates an overactive thyroid (hyperthyroidism). Free T4 is more accurate than total T4 because it reflects bioavailable hormone. The thyroid requires iodine to synthesize hormone, which is why iodine agents are therapeutically useful.

Hyperthyroidism is a state of excess thyroid hormone. Graves' disease (autoimmune, involving TSH-receptor antibodies) is the most common cause. The excess hormone accelerates metabolism: weight loss despite increased appetite, heat intolerance, diaphoresis, tachycardia (may progress to atrial fibrillation), palpitations, hypertension, nervousness, tremor, insomnia, and diarrhea. Physical signs include warm moist skin, fine tremor, and hyperreflexia. Graves'-specific features are exophthalmos (bulging eyes from orbital immune infiltration) and goiter (enlarged thyroid). Labs show elevated free T4 and T3 with suppressed TSH. Radioactive iodine uptake is elevated in Graves' (helps differentiate from thyroiditis, where uptake is low).

Methimazole and PTU both inhibit thyroid peroxidase, blocking the coupling of iodine into thyroid hormone. PTU has an additional advantage: it inhibits peripheral conversion of T4 to T3 (the more potent form). Both drugs take 2–4 weeks to show clinical effect because the gland has a hormone reservoir. PTU is preferred in the first trimester of pregnancy (methimazole is teratogenic, causing rare methimazole embryopathy). Both drugs can cause agranulocytosis (1–2 per 1000 patients), which is life-threatening. Patients must report sore throat, fever, or unusual bleeding immediately, as these are early signs of bone-marrow suppression. Liver toxicity is also possible with both but is more common with PTU.

Iodine (in forms like Lugol's solution [5% iodine + 10% KI] or saturated solution of potassium iodide [SSKI]) acts acutely to reduce thyroid hormone release and gland vascularity. The effect is fast (1–3 days) but temporary (2–3 weeks). Iodine is used pre-operatively to reduce bleeding during thyroidectomy. It must be given *after* antithyroid drugs (PTU/methimazole) are started; if given first, it may increase hormone synthesis and worsen hyperthyroidism. Iodine must be diluted in juice or water and given through a straw (stains teeth and throat). Never use aspirin in hyperthyroid patients because it displaces thyroid hormone from binding proteins, worsening the condition.

Thyroid storm is a life-threatening exacerbation of hyperthyroidism, usually triggered by infection, surgery, anesthesia, or stress in a patient with poorly controlled or untreated hyperthyroidism. The pathophysiology involves a sudden massive surge of thyroid hormone release and extreme adrenergic sensitivity. Cardinal features are severe hyperthermia (often 39–41°C or higher), severe tachycardia (may exceed 140 bpm), tachypnea, hypertension, profound agitation/delirium, vomiting, diarrhea, and potential progression to shock and coma. The mortality rate is 5–15% even with treatment. This is a *true* emergency requiring ICU-level care.

Hypothyroidism is a state of insufficient thyroid hormone. Hashimoto's thyroiditis (chronic autoimmune thyroiditis) is the most common cause in iodine-sufficient regions. Other causes include post-thyroidectomy, post-radioactive iodine therapy, iodine deficiency, medications (lithium, amiodarone), and pituitary/hypothalamic disease (secondary hypothyroidism). The hormone deficit slows metabolism: weight gain, cold intolerance, fatigue/lethargy, bradycardia, constipation, dry skin and hair, hair loss (especially outer third of eyebrows), depression, slowed cognition, and delayed reflexes. A hallmark finding is non-pitting edema (myxedema) of the face and periorbital area. Labs show low free T4 and elevated TSH (in primary disease). The onset is often insidious, and hypothyroidism is frequently undiagnosed or misattributed to depression or aging.

Levothyroxine (synthetic T4, brand name Synthroid) is the standard treatment for hypothyroidism. It is taken orally, usually once daily. Absorption is maximized on an empty stomach; it should be taken 30–60 minutes before breakfast. Many substances impair absorption: calcium supplements, iron pills, antacids, phosphate binders, and even certain foods like soy and fiber. Therefore, levothyroxine should be separated from these by at least 4 hours. The dose is individualized and adjusted based on TSH levels (target usually 0.5–2.0 mIU/L for most patients). Effect is gradual; steady state is reached in 6–8 weeks. Patients must take the same dose at the same time daily and never stop abruptly—hypothyroidism is a lifelong condition. In elderly patients or those with cardiac disease, dosing should start low and increase slowly because too rapid replacement increases myocardial oxygen demand, risking angina or arrhythmias.

Myxedema coma is a rare but life-threatening decompensation of severe hypothyroidism, usually precipitated by infection, cold exposure, or sedative drugs in a patient with unrecognized or poorly treated hypothyroidism. The pathophysiology involves profound slowing of metabolism, respiratory depression, altered consciousness, and loss of thermoregulation. The clinical tetrad is: severe hypothermia (often 32–35°C), hypotension (sometimes profound shock), hypoglycemia, and hypoventilation with CO2 retention (respiratory depression). Mental status progresses from lethargy to coma. The mortality rate is 5–15% to 50% depending on severity and comorbidities. Precipitating factors include infection (especially pneumonia), sedatives, anesthetics, trauma, and cold exposure. This is a true ICU emergency.

After thyroidectomy, the immediate post-operative priorities are airway protection, hemorrhage prevention, and early detection of complications. The patient is positioned semi-Fowler's with the head and neck supported (avoid hyperextension or extreme neck movement for the first 24 hours). Tracheostomy set, oxygen, and suction must be at the bedside because hemorrhage or edema can compromise the airway. The nurse must assess the anterior dressing regularly but also check *behind* the neck and along the sides (blood can track backward). Monitor for signs of hemorrhage: increased pain, swelling, tightness in the neck, difficulty swallowing, or stridor. Laryngeal nerve damage (unilateral or bilateral) causes hoarseness or voice changes; the nurse should assess voice periodically. Bilateral laryngeal nerve damage (rare) causes stridor and airway obstruction. Parathyroid gland injury causes hypocalcemia and tetany; watch for tingling, muscle spasms, and positive Chvostek's and Trousseau's signs. Have calcium gluconate ready. Thyroid hormone levels drop post-op, but replacement is delayed until the gland is fully healed.

PTH is released by the parathyroid glands in response to low serum calcium. PTH has three effects: (1) it stimulates osteoclasts in bone to release calcium and phosphate into the blood (bone resorption), (2) it increases renal tubular reabsorption of calcium and decreases reabsorption of phosphate (causing phosphaturia), and (3) it stimulates conversion of 25-hydroxyvitamin D to active 1,25-dihydroxyvitamin D in the kidney, which increases GI absorption of calcium. The net effect of PTH is to *raise* serum calcium and *lower* serum phosphate. They move in opposite directions: when calcium is high, phosphate is low, and vice versa. Normal serum calcium is 8.5–10.5 mg/dL (corrected for albumin). The calcium-phosphate feedback is essential for understanding parathyroid disorders.

Hyperparathyroidism results from excessive PTH secretion, most commonly from a parathyroid adenoma (80%), hyperplasia, or rarely, carcinoma. The excessive PTH causes persistent hypercalcemia and hypophosphatemia. The classic mnemonic is 'bones, stones, groans, and psychiatric moans': (1) Bones—PTH causes osteoclast activity, bone resorption, and loss of bone mineral density, leading to osteoporosis and pathologic fractures. (2) Stones—hypercalcemia increases urinary calcium, promoting nephrolithiasis (kidney stones). (3) Groans—GI symptoms from hypercalcemia include nausea, vomiting, constipation, and peptic ulcer disease. (4) Psychiatric moans—neuropsychiatric symptoms from hypercalcemia include fatigue, depression, anxiety, irritability, and in severe cases, altered consciousness ('stones make bones, bones make groans'). Other symptoms of hypercalcemia include polyuria, polydipsia (from nephrogenic DI-like effect), muscle weakness, and hypertension. Lab findings: elevated serum calcium (>10.5 mg/dL), low serum phosphate (<2.5 mg/dL), elevated PTH, and elevated 1,25-vitamin D.

Hypoparathyroidism results from deficient PTH secretion or end-organ resistance to PTH. The most common cause is accidental removal or injury of the parathyroid glands during thyroid or parathyroid surgery. Other causes include autoimmune destruction, infiltrative disease (hemochromatosis, sarcoidosis), or genetic mutations (DiGeorge syndrome involves thymic and parathyroid hypoplasia). The deficit in PTH causes hypocalcemia and hyperphosphatemia. Hypocalcemia triggers neuromuscular hyperexcitability: paresthesias (especially perioral and in the fingertips), muscle cramps and spasms, tetany (involuntary muscle contractions), laryngospasm (spasm of the larynx, potentially obstructing the airway), and seizures. Two clinical signs of latent tetany are diagnostic: (1) Chvostek's sign—tapping the facial nerve anterior to the ear causes twitching of the mouth and nose (positive if twitching occurs). (2) Trousseau's sign—inflating a blood-pressure cuff on the arm above systolic pressure for a few minutes causes carpal spasm (involuntary flexion of the wrist and fingers). Lab findings: low serum calcium (<8.5 mg/dL), elevated serum phosphate (>4.5 mg/dL), low or absent PTH, and low 1,25-vitamin D.

Hypercalcemic crisis occurs when serum calcium rises acutely above 14 mg/dL, usually from hyperparathyroidism, malignancy, or excessive vitamin D/A intake. Symptoms include nausea, vomiting, polyuria, polydipsia, constipation, dehydration, hypotension, cardiac arrhythmias (shortened QT interval on ECG), altered mental status, and coma. The mechanism involves both direct effects of high calcium and resultant dehydration. Hypocalcemic crisis (severe acute hypocalcemia <6.5 mg/dL) presents with tetany, seizures, laryngospasm (potentially fatal), cardiac arrhythmias (prolonged QT, torsades de pointes), and altered consciousness. Both are medical emergencies requiring ICU-level care. Hypercalcemic crisis is managed with aggressive hydration, loop diuretics, bisphosphonates, calcitonin, and treatment of the underlying cause. Hypocalcemic crisis is managed with IV calcium gluconate (10% solution, given slowly through a central line if possible, because extravasation causes tissue necrosis), vitamin D, and magnesium replacement if hypomagnesemia is present.

For endocrine disorders, relevant NANDA-I nursing diagnoses include: Excess fluid volume or Deficient fluid volume (depending on the disorder), Imbalanced nutrition: more or less than body requirements, Fatigue, Anxiety, Decreased cardiac output (for hyperthyroidism), Risk for injury (from osteoporosis, neuromuscular instability), Knowledge deficit, and Risk for electrolyte imbalance. For acute crises (thyroid storm, myxedema coma, hypercalcemic/hypocalcemic crises), priorities shift to airway, breathing, circulation (ABCs) using Maslow's hierarchy. Physiologic needs (oxygenation, hemodynamic stability, electrolyte balance, seizure prevention) take precedence. Once acute stability is achieved, attention moves to fluid/electrolyte balance, nutrition, and safety. For chronic disorders, the focus is on medication adherence, patient education, and prevention of complications. Prioritization frameworks: in SIADH, fluid restriction and seizure precautions are top priorities; in DI, fluid replacement and DDAVP administration are critical; in hyperthyroidism, heart rate and cardiac rhythm monitoring; in hypothyroidism (non-emergent), medication adherence and symptom management; in parathyroid disorders, calcium levels and neuromuscular status.

Patient education is a cornerstone of nursing care for chronic endocrine disorders (RA 9173 emphasizes patient education as a core nursing function). For levothyroxine: take on an empty stomach in the morning, 30–60 minutes before breakfast, at the same time daily, never stop abruptly, separate from calcium/iron/antacids by 4 hours, and report palpitations, chest pain, weight change, or heat/cold intolerance. For antithyroid drugs (PTU/methimazole): report sore throat, fever, unusual bleeding, or bruising (agranulocytosis), and understand that effects take 2–4 weeks. For radioactive iodine: most patients eventually become hypothyroid and need lifelong levothyroxine; radiation safety (avoid prolonged contact with pregnant women and small children for a few days). For DDAVP (desmopressin) in DI: report signs of over-treatment (headache, drowsiness, weight gain, nausea = water retention/hyponatremia); carry medical alert identification; and ensure consistent access to the medication (especially important in the Philippine context where medication supply can be variable). For parathyroid disorders: maintain adequate calcium and vitamin D intake, report signs of hypercalcemia (nausea, bone pain, kidney stones) or hypocalcemia (tingling, muscle spasms), and seek regular follow-up for lab monitoring. In the Philippine context, where many patients may have limited access to care and medication, emphasizing the importance of compliance and providing simple, clear written instructions (possibly in Tagalog or local language) is crucial.

SIADH and diabetes insipidus are exact opposites in pathophysiology and clinical presentation. SIADH has excess ADH → water retention → dilution → LOW sodium (dilutional hyponatremia) + concentrated urine + low serum osmolality. DI has deficient ADH → water loss → dehydration → HIGH sodium (hypernatremia) + dilute urine + high serum osmolality. The management is also opposite: SIADH uses FLUID RESTRICTION; DI uses FLUID REPLACEMENT + DDAVP. Understanding one disorder immediately illuminates the other. This pairing is a hallmark of NLE testing: 'too much versus too little' of the same hormone.

Hyperthyroidism and hypothyroidism represent opposite disruptions of thyroid hormone levels and metabolism. Hyperthyroidism = excess hormone = accelerated metabolism = weight loss, heat intolerance, tachycardia, nervousness, diarrhea, warm moist skin. Hypothyroidism = deficient hormone = slowed metabolism = weight gain, cold intolerance, fatigue, bradycardia, constipation, dry skin, myxedema. Each symptom in one disorder is the opposite in the other, making side-by-side comparison an excellent learning strategy. Lab findings are also opposite: hyperthyroidism has elevated T4/T3 and LOW TSH; hypothyroidism has low T4/T3 and HIGH TSH. The inverse TSH relationship is the key to understanding thyroid disease.

These are the two critical emergencies in thyroid disease, representing extreme decompensation of hyperthyroidism and hypothyroidism, respectively. Thyroid storm (excess) = HIGH fever, severe tachycardia, hypertension, agitation, vomiting → cardiovascular collapse. Myxedema coma (deficiency) = HYPOthermia, bradycardia, HYPOtension, hypoventilation → respiratory failure/coma. Both have mortality rates of 5–15% to 50% depending on severity. The management is opposite: thyroid storm requires cooling (NOT aspirin), beta-blockers, antithyroid drugs, iodine, corticosteroids. Myxedema coma requires gradual rewarming, IV levothyroxine, airway support, IV fluids/glucose, corticosteroids. Neither condition can be managed in a routine ward; both require ICU-level care.

Hyperparathyroidism (excess PTH) → HIGH calcium + LOW phosphate; hypoparathyroidism (deficient PTH) → LOW calcium + HIGH phosphate. The calcium-phosphate inverse relationship is absolute: PTH raises calcium by pulling from bone, increasing renal reabsorption, and promoting GI absorption; it lowers phosphate by promoting renal excretion. In excess, all these effects go too far (high calcium, low phosphate, bone loss). In deficiency, none of these effects occur (low calcium, high phosphate, neuromuscular hyperexcitability). The clinical manifestations are also opposite: hyperparathyroidism presents with 'bones, stones, groans, moans' (bone loss, kidney stones, GI upset, psychiatric symptoms); hypoparathyroidism presents with tetany, paresthesias, Chvostek's/Trousseau's signs (neuromuscular over-excitability).

TSH (thyroid-stimulating hormone from the anterior pituitary) is the master regulator of the thyroid. It responds to TRH from the hypothalamus and is suppressed by thyroid hormone (negative feedback). In primary thyroid disease (disease in the gland itself), TSH and thyroid hormone move in OPPOSITE directions: if the gland is overactive (hyperthyroidism), it produces excess hormone, which suppresses TSH (low TSH + high T4 = hyperthyroid). If the gland is underactive (hypothyroidism), it produces insufficient hormone, which allows TSH to rise (high TSH + low T4 = hypothyroid). This inverse relationship is the cornerstone of thyroid lab interpretation. TSH is the most sensitive test because it amplifies small changes in hormone levels.

Both sodium (in SIADH) and calcium (in hypoparathyroidism) dysregulation present with neurologic symptoms. Severe hyponatremia (SIADH) causes cerebral edema: headache, confusion, lethargy, seizures, coma. Severe hypocalcemia (hypoparathyroidism) causes neuromuscular hyperexcitability: paresthesias, muscle cramps, tetany, seizures, laryngospasm. Both can present with seizures, but the mechanism is different (cerebral edema vs. neuromuscular over-excitability). Both require rapid recognition and treatment. The danger in SIADH is not just the low sodium but its neurologic consequences; the danger in hypoparathyroidism is not just low calcium but laryngospasm (potential airway obstruction). Nurses must include neuro assessment and airway monitoring in both situations.

Levothyroxine (synthetic T4) must be absorbed well to maintain adequate hypothyroid management. Multiple substances impair absorption: calcium (in milk, supplements), iron, antacids, phosphate binders, fiber supplements, soy products, and certain timing (with meals). If a patient with hypothyroidism takes levothyroxine with breakfast (containing calcium and fiber) or with calcium supplements, absorption is impaired, and serum T4 remains low despite apparently adequate dosing. This can lead to persistent hypothyroid symptoms, TSH elevation, and misinterpretation as 'need for higher dose' when the real problem is absorption. Educating patients about proper administration is thus critical for treatment success.

Antithyroid drugs (PTU and methimazole) block thyroid hormone synthesis but take 2–4 weeks to show clinical effect because the gland has a pre-formed hormone reservoir. During this waiting period, the patient remains symptomatic (tachycardia, tremor, anxiety, palpitations). Beta-blockers (especially propranolol, which also inhibits peripheral conversion of T4 to T3) are used immediately for symptom relief while waiting for antithyroid drugs to work. This combination therapy (antithyroid drug + beta-blocker) is the standard approach. Iodine is added pre-operatively (after antithyroid drugs are started) to reduce gland vascularity for surgery, but iodine is not a long-term treatment. Understanding this time sequence is crucial: jump-starting with beta-blockers prevents the patient from suffering during the lag phase of antithyroid drug effect.

The thyroid gland lies in the neck with critical structures nearby: the laryngeal nerves (recurrent and superior laryngeal) run along the thyroid, and the parathyroid glands (four small glands embedded in or behind the thyroid capsule) are at risk during thyroidectomy. Recurrent laryngeal nerve injury causes unilateral hoarseness; bilateral injury causes airway obstruction (stridor, potential need for tracheostomy). Parathyroid injury (especially if more than one is removed) causes acute hypocalcemia/tetany and long-term hypoparathyroidism. Hemorrhage is also a risk because the thyroid is a highly vascular organ; bleeding can be anterior (visible under the dressing) or posterior (tracking behind the neck, potentially compressing the airway without obvious external signs). Understanding the anatomy explains why post-thyroidectomy nursing includes: airway precautions, hemorrhage checks (front and back), voice assessment, and calcium/Chvostek's/Trousseau's monitoring.